Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting
Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
Boyang Zheng¹, Mianbo Wang² and Murray Baron³, ¹Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, ²Lady Davis Institute for Medical Research, Montreal, QC, Canada, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Oliver Distler¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer AG, Berlin, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Ana Paula Luppino-Assad¹, Adriana Bortoluzzo², Henrique Carriço da Silva³, Danieli Andrade⁴ and Percival Sampaio-Barros⁴, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, ²c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, ⁴Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
Abstract Number: 903 • 2018 ACR/ARHP Annual Meeting
Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)
Oliver Distler¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Dinesh Khanna¹⁰, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer Healthcare Co. Ltd.,, Beijing, China, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: There are few disease-modifying therapies for the treatment of systemic sclerosis (SSc), particularly the more severe diffuse cutaneous form (dcSSc). The soluble guanylate cyclase…
Abstract Number: 1108 • 2018 ACR/ARHP Annual Meeting
Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment
Julia Z. Adamska^1,2, Leslie Crofford³, Daniel E. Furst^4,5, Ellen Goldmuntz⁶, Lynette Keyes-Elstein⁷, Maureen D. Mayes⁸, Peter McSweeney⁹, Richard Nash⁹, Ashley Pinckney¹⁰, Beverly Welch¹¹, Keith Sullivan¹² and William H. Robinson^1,2, ¹Stanford University, Stanford, CA, ²VA Palo Alto Health Care System, Palo Alto, CA, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of Washington, Seattle, WA, ⁶NIAID, NIH, Bethesda, MD, ⁷Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Colorado Blood Cancer Institute, Denver, CO, ¹⁰Rho Federal Systems, Inc., Chapel Hill, NC, ¹¹National Institutes of Health, Bethesda, MD, ¹²Duke University Medical Center, Durham, NC
Background/Purpose: Myeloablative autologous hematopoietic stem-cell transplantation (HSCT) was recently demonstrated to provide benefit over monthly cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis…
Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
Håvard Fretheim¹, Oyvind Midtvedt¹, Anders Heiervang Tennøe¹, Henriette Didriksen¹, Torhild Garen¹, Espen Bækkevold¹, Johannes R. Hov¹, Knut EA Lundin², Marius Trøseid¹, Øyvind Molberg¹ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²Dept of gastroenterology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Anna Leslie³, Voon H. Ong⁴ and Christopher P. Denton⁵, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
Abstract Number: 1695 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease
Robert L. Mango¹, Eric L. Matteson², Cynthia S. Crowson³, Jay H. Ryu⁴ and Ashima Makol², ¹Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical…
Abstract Number: 1713 • 2017 ACR/ARHP Annual Meeting
Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients
Edward Stern¹, Sandra Guerra¹, Harry Chinque¹, David Gonzalez Serna², Markella Ponticos¹, Javier Martin², Maureen D. Mayes³, Shervin Assassi⁴, Carmen Fonseca¹ and Christopher Denton⁵, ¹UCL Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ²Instituto de Parasitología y Biomedicina López-Neyra, Granada, Spain, ³Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC), characterised by accelerated hypertension and acute kidney injury, is a life-threatening complication of systemic sclerosis (SSc). Most SSc cases have…
Abstract Number: 1922 • 2017 ACR/ARHP Annual Meeting
Cell Type Specific Gene Expression Analysis of Early Systemic Sclerosis Skin Shows a Prominent Activation Pattern of Innate and Adaptive Immune System in the Prospective Registry for Early Systemic Sclerosis (PRESS) Cohort
Shervin Assassi¹, Dinesh Khanna², Monique Hinchcliff³, Virginia D. Steen⁴, Faye Hant⁵, Jessica K. Gordon⁶, Ami A. Shah⁷, Jun Ying⁸, William Swindell⁹, Wenjin Zheng¹⁰, Lisha Zhu¹⁰, Victoria K. Shanmugam¹¹, Robyn T. Domsic¹², Flavia V. Castelino¹³, Elana J. Bernstein¹⁴ and Tracy M. Frech¹⁵, ¹University of Texas McGovern Medical School, Houston, TX, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, Northwestern Medicine, Chicago, IL, ⁴Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Dermatology, University of Michigan - Ann Arbor, Ann Arbor, MI, ¹⁰University of Texas - School of Biomedical Informatics, Houston, TX, ¹¹Rheumatology, The George Washington University, Washington, DC, ¹²Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹³Rheumatology, Harvard Medical School, Boston, MA, ¹⁴Rheumatology, Columbia University, New York, NY, ¹⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: To examine the global gene expression profile in patients with very early diffuse systemic sclerosis (SSc). Methods: Skin biopsies were obtained from patients enrolled…
Abstract Number: 1923 • 2017 ACR/ARHP Annual Meeting
Single Cell RNA Sequencing Reveals a Signature of Endothelial Injury in Scleroderma Skin
Sokratis Apostolidis¹, Giuseppina Stifano², Tracy Tabib³, Lisa Rice², Christina Morse³, Bashar Kahaleh⁴ and Robert A. Lafyatis³, ¹Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Boston University School of Medicine, Boston, MA, ³Medicine, Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Vascular injury is a hallmark event in the pathogenesis of Systemic Sclerosis (SSc). Endothelial dysfunction happens early in the course of the disease and…
Abstract Number: 2665 • 2017 ACR/ARHP Annual Meeting
Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis
Tracy M. Frech¹, Shervin Assassi², Elana J. Bernstein³, Flavia V. Castelino⁴, Robyn T. Domsic⁵, Jessica K. Gordon⁶, Faye Hant⁷, Monique Hinchcliff⁸, Bernie LaSalle⁹, Victoria K. Shanmugam¹⁰, Virginia D. Steen¹¹ and Dinesh Khanna¹², ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Texas McGovern Medical School, Houston, TX, ³Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁴Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁸Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹University of Utah, Salt Lake City, UT, ¹⁰Rheumatology, The George Washington University, Washington, DC, ¹¹Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹²University of Michigan, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) cohort is an early diffuse cutaneous systemic sclerosis (dcSSc) that provides an opportunity to assess the…
Abstract Number: 2674 • 2017 ACR/ARHP Annual Meeting
The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis
Janet E. Pope¹, Murray Baron², Tatiana Nevskaya³, Carl Baxter⁴ and Dena Ramey⁵, ¹Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology Division, St. Joseph’s Health Care London, London, ON, Canada, ⁴Global Outcomes Research, MSD Ltd, Hoddesdon, United Kingdom, ⁵Epidemiology, Merck & Co., Upper Gwynedd, PA
Background/Purpose: To estimate whether severity of skin thickness is associated with disease severity, function, quality of life (QoL) and progression of internal organ involvement over…
Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Daphne Peelen¹, Ben Zwezerijnen², Esther Nossent¹, Lilian Meijboom¹, Otto Hoekstra³, Conny van der Laken⁴ and Alexandre Voskuyl⁴, ¹VUmc, Amsterdam, Netherlands, ²Nuclear Medicine, VUmc, Amsterdam, Netherlands, ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
Abstract Number: 2690 • 2017 ACR/ARHP Annual Meeting
Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy
Anna Gill¹, Svetlana I. Nihtyanova², Pratima Chowdary³ and Christopher Denton¹, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Department of Haematology, Royal Free Hospital, London, United Kingdom
Background/Purpose: D-dimers are degradation products of cross linked fibrin and are biomarkers of activation of the coagulation system. Plasma D-dimer levels can be raised in…

1
2
3
…
8
Next Page »